-
公开(公告)号:EP3142666A1
公开(公告)日:2017-03-22
申请号:EP15793503.2
申请日:2015-05-18
申请人: RaQualia Pharma Inc.
IPC分类号: A61K31/454 , A61P1/04 , A61P3/10 , A61P5/14 , A61P17/00 , A61P25/00 , A61P25/06 , A61P25/16 , A61P31/12
摘要: This invention relates to 4-{[4-({([4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]-oxy}methyl)piperidin-1-yl]methyl}tetrahydro-2H-pyran-4-carboxylic acid for use in therapeutic treatment of the human body. In particular, it relates to the compound having selective 5-HT4 receptor agonism, which is useful for treating gastroparesis, or preventing or delaying the onset or the progression of gastroparesis.
摘要翻译: 本发明涉及4 - {[4 - ({([4-(2,2,2-三氟乙氧基)-1,2-苯并异恶唑-3-基]氧基}甲基哌啶-1-基]甲基}四氢-2H- - 吡喃-4-羧酸,特别涉及具有选择性5-HT 4受体激动作用的化合物,其可用于治疗胃轻瘫,或预防或延缓发作或进展 胃轻瘫。
-